Top Markets
Coin of the day
Biocept, Inc. Biocept, Inc.

Biocept, Inc.

BIOC
주식 순위 #41381
Biocept, Inc. is a company specializing in molecular diagnostics for cancer,... Biocept, Inc. is a company specializing in molecular diagnostics for cancer, primarily focused on developing and commercializing advanced diagnostic assays based on proprietary technology. These tests analyze circulating tumor cells (CTCs) and cell-free tumor DNA and RNA (ctDNA/ctRNA), primarily using standard blood samples. These assays furnish crucial insights to healthcare professionals, enabling them to identify specific genetic changes (oncogenic alterations) that qualify certain cancer patients for targeted therapies. This information is vital throughout the patient journey: at initial diagnosis, during disease progression, and for ongoing monitoring to detect the emergence of treatment resistance. Their diagnostic portfolio extends to various solid tumor types, including breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. Beyond blood-based diagnostics, Biocept offers specialized testing services for cerebrospinal fluid (CSF), analyzing tumor cells, ctDNA, and ctRNA. These services cater to a broad spectrum of medical specialists, such as medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, and pathologists. Furthermore, the company supports pharmaceutical and biopharmaceutical companies, along with clinical research organizations (CROs), through its clinical trial and research services. Additionally, Biocept provides RT-PCR testing for COVID-19. In strategic partnerships, Biocept collaborates with CLEARED4 on a system designed to track and manage COVID-19 testing requirements and results for clients. Another collaboration involves Protean BioDiagnostics, Inc., focusing on research into the efficacy of Biocept's proprietary Target Selector molecular assay for determining EGFR status in non-small cell lung cancer (NSCLC) patients. Established in 1997, Biocept, Inc. operates from its headquarters in San Diego, California.
주가
$0.053
마지막 동기화: 2023-11-21
시가총액
$23.67K
변동 (1일)
-11.67%
변동 (1년)
0.00%
국가
US
거래 Biocept, Inc. (BIOC)

카테고리

B의 시가 총액을 가진 BIOC의 가격
Biocept, Inc. Biocept, Inc.
BIOC
$0.053
의 시가총액 Biocept, Inc.(BIOC)
시가총액: $23.67K
August 2026 기준으로 Biocept, Inc.의 시가총액은 $23.67K입니다. 이는 당사 데이터에 따르면 Biocept, Inc.이 세계에서 41381st번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2014부터 2026까지 Biocept, Inc.의 시가총액 기록
BIOC 가장 인기있는 상위 5 가지 stocks과 비교하여
BIOC의 가격 자산 b b의 시장 결과
Biocept, Inc. Biocept, Inc.
$12,055,176 $23.67K
$5.383T +22,745,615,270.83%
Biocept, Inc. Biocept, Inc.
$9,905,480 $23.67K
$4.423T +18,689,585,037.78%
Biocept, Inc. Biocept, Inc.
$9,316,485 $23.67K
$4.160T +17,578,272,882.74%
Biocept, Inc. Biocept, Inc.
$8,203,424 $23.67K
$3.663T +15,478,157,611.28%
Biocept, Inc. Biocept, Inc.
$6,474,446 $23.67K
$2.891T +12,215,936,550.32%